clinical activity and tolerability of the ret inhibitor blue-667 in patients with advanced ret f...
Published 5 years ago • 126 plays • Length 6:09Download video MP4
Download video MP3
Similar videos
-
1:22
targeting ret alterations with selective inhibitor blu-667
-
4:05
first-in-human trial results of ret targeted blu-667
-
8:42
treating ret alterations with novel therapy blu-667
-
1:14
dr. subbiah on safety and efficacy of blu-667 in ret-altered solid tumors
-
6:10
the future of ret inhibition in clinical practice
-
2:33
dr. gainor on potential with blu-667 in ret nsclc
-
9:54
efficacy and safety of selpercatinib in ret fusion-positive cancers other than lung or thyroid c...
-
30:28
btki resistance mutations in chronic lymphocytic leukemia (cll)
-
6:29
a blood test for cancer
-
11:15
sensitivity, specificity, ppv, npv
-
2:01
tirabrutinib, a second-generation btki, in the treatment of symptomatic wm and bing-neel syndrome
-
6:42
selpercatinib benefit, with or without pembro, in first-line advanced ret fusion-positive nsclc
-
6:04
arrow: clinical activity of pralsetinib in ret-fusion positive solid tumors
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
6:09
ret inhibition in ret aberrant cancers
-
58:12
pralsetinib for advanced or metastatic ret-altered thyroid cancer with dr. vivek subbiah
-
1:19
phase i/ii trial of ep0031, a next generation selective ret inhibitor
-
4:58
treatment of nsclc with ret fusions
-
5:45
subtypes in nsclc: braf and ret
-
1:27
the future of ret-specific therapy
-
1:53
retevmo for thyroid cancer saves tanner’s life!
-
6:08
next-generation selective ret inhibitor shows initial promise with ret-altered solid tumours